1652 Stock Overview An investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Fusen Pharmaceutical Company Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Fusen Pharmaceutical Historical stock prices Current Share Price HK$0.57 52 Week High HK$1.28 52 Week Low HK$0.56 Beta 0.53 1 Month Change -16.18% 3 Month Change -40.00% 1 Year Change -57.46% 3 Year Change -50.00% 5 Year Change -89.31% Change since IPO -77.56%
Recent News & Updates
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price Dec 18
Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China Oct 22
Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection Oct 17
First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023) Oct 01
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024 Aug 22
Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024 Aug 20 See more updates
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price Dec 18
Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China Oct 22
Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection Oct 17
First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023) Oct 01
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024 Aug 22
Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024 Aug 20
Fusen Pharmaceutical Company's Subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces Acceptance of Clinical Trial Application for ``SY617'' Jul 12
New minor risk - Market cap size Jun 27
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky May 21
Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024 Apr 28
CEO & Executive Director recently bought HK$224k worth of stock Apr 25 Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I) Apr 05
Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27% Mar 31
Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022) Mar 30
Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 19
First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022) Oct 01
First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022) Aug 31
Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023 Aug 18
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023 Aug 13
Executive Chairman recently bought HK$84k worth of stock Apr 17
CEO & Executive Director recently bought HK$1.0m worth of stock Apr 01
Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021) Mar 30
Executive Chairman recently bought HK$1.1m worth of stock Jan 31
Executive Chairman recently bought HK$918k worth of stock Jan 10
CEO & Executive Director recently bought HK$375k worth of stock Jan 03
Executive Chairman recently bought HK$791k worth of stock Dec 19
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky Dec 14
Executive Chairman recently bought HK$2.3m worth of stock Nov 27
Less than half of directors are independent Nov 16
CEO & Executive Director recently bought HK$2.2m worth of stock Nov 10
Executive Chairman recently bought HK$2.0m worth of stock Nov 02
CEO & Executive Director recently bought HK$2.0m worth of stock Oct 25
CEO & Executive Director recently bought HK$658k worth of stock Oct 11
CEO & Executive Director recently bought HK$79k worth of stock Sep 22
CEO & Executive Director recently bought HK$1.9m worth of stock Sep 14
CEO & Executive Director recently bought HK$1.9m worth of stock Sep 10
First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021) Sep 02
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022 Aug 30
Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022 Aug 21
Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022 Aug 17
CEO & Executive Director recently bought HK$157k worth of stock Aug 01
CEO & Executive Director recently bought HK$1.9m worth of stock Jul 15
CEO & Executive Director recently bought HK$1.9m worth of stock Jun 11
Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021 Jun 01
Less than half of directors are independent Apr 27
Investor sentiment improved over the past week Dec 22
CEO & Executive Director recently bought HK$856k worth of stock Dec 22
CEO & Executive Director recently bought HK$2.1m worth of stock Dec 12
Investor sentiment deteriorated over the past week Dec 07
First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020) Sep 26
Investor sentiment deteriorated over the past week Sep 19
Investor sentiment improved over the past week Sep 03
Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly Sep 02
First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020) Aug 25
Investor sentiment deteriorated over the past week Jun 23
Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020 May 27
Investor sentiment deteriorated over the past week May 12
Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019) Apr 25
Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly Apr 02
Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019) Apr 02
Investor sentiment improved over the past week Mar 29
Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021 Mar 20
A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns Mar 06
New 90-day low: HK$4.17 Feb 24
We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide Feb 08
Company Secretary has left the company Feb 03
Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021 Jan 31
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals? Jan 18
Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet? Dec 28
Investor sentiment deteriorated over the past week Dec 22
Investor sentiment deteriorated over the past week Dec 18
Investor sentiment deteriorated over the past week Dec 14
What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition Dec 07
Market bids up stock over the past week Dec 07
New 90-day high: HK$6.00 Nov 20
If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns Nov 20
Market bids up stock over the past week Nov 05
New 90-day high: HK$4.69 Nov 03
Market bids up stock over the past week Oct 23
First half earnings released Sep 16
New 90-day high - HK$3.78 Sep 02
First half earnings released Sep 01
Fusen Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 31, 2020 Aug 22 Shareholder Returns 1652 HK Pharmaceuticals HK Market 7D -9.5% 2.8% 2.3% 1Y -57.5% 3.5% 24.5%
See full shareholder returns
Return vs Market: 1652 underperformed the Hong Kong Market which returned 24.5% over the past year.
Price Volatility Is 1652's price volatile compared to industry and market? 1652 volatility 1652 Average Weekly Movement 7.1% Pharmaceuticals Industry Average Movement 5.0% Market Average Movement 6.4% 10% most volatile stocks in HK Market 13.7% 10% least volatile stocks in HK Market 3.0%
Stable Share Price: 1652 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1652's weekly volatility (7%) has been stable over the past year.
About the Company Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers cardio cerebrovascular, blood pressure and sugar reduction, tonifying, qi-regulating, anti-anemia, antibacterial and anti-inflammatory, gastrointestinal tract, and expectorant cough category products.
Show more Fusen Pharmaceutical Company Limited Fundamentals Summary How do Fusen Pharmaceutical's earnings and revenue compare to its market cap? 1652 fundamental statistics Market cap HK$421.40m Earnings (TTM ) -HK$95.84m Revenue (TTM ) HK$454.76m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1652 income statement (TTM ) Revenue CN¥425.49m Cost of Revenue CN¥199.23m Gross Profit CN¥226.26m Other Expenses CN¥315.93m Earnings -CN¥89.67m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.12 Gross Margin 53.18% Net Profit Margin -21.08% Debt/Equity Ratio 67.0%
How did 1652 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 19:28 End of Day Share Price 2025/02/07 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Fusen Pharmaceutical Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
